Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect Factor Xa (fXa) Inhibitors in Healthy Volunteers.

NCT03551730 is registered in ClinicalTrials.gov with Portola Pharmaceuticals as lead sponsor.

NCT NCT03551730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03551730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect Factor Xa (fXa) Inhibitors in Healthy Volunteers.
Lead sponsor
Portola Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2012
Completion date
September 30, 2015
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers